145 related articles for article (PubMed ID: 29940414)
21. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.
Skildum A; Dornfeld K; Wallace K
Breast Cancer Res Treat; 2011 Oct; 129(3):785-97. PubMed ID: 21128112
[TBL] [Abstract][Full Text] [Related]
22. Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis.
Mallano T; Palumbo-Zerr K; Zerr P; Ramming A; Zeller B; Beyer C; Dees C; Huang J; Hai T; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2016 Mar; 75(3):586-92. PubMed ID: 25589515
[TBL] [Abstract][Full Text] [Related]
23. Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
Hao ZF; Su YM; Wang CM; Yang RY
Tumour Biol; 2015 Mar; 36(3):1471-6. PubMed ID: 25371069
[TBL] [Abstract][Full Text] [Related]
24. Pre-activated human mesenchymal stromal cells in combination with doxorubicin synergistically enhance tumor-suppressive activity in mice.
Yoon N; Park MS; Peltier GC; Lee RH
Cytotherapy; 2015 Oct; 17(10):1332-41. PubMed ID: 26227206
[TBL] [Abstract][Full Text] [Related]
25. Up-Regulation of Activating Transcription Factor 3 in Human Fibroblasts Inhibits Melanoma Cell Growth and Migration Through a Paracrine Pathway.
Zu T; Wen J; Xu L; Li H; Mi J; Li H; Brakebusch C; Fisher DE; Wu X
Front Oncol; 2020; 10():624. PubMed ID: 32373541
[TBL] [Abstract][Full Text] [Related]
26. ATF3 mediates the inhibitory action of TNF-α on osteoblast differentiation through the JNK signaling pathway.
Jeong BC
Biochem Biophys Res Commun; 2018 May; 499(3):696-701. PubMed ID: 29605296
[TBL] [Abstract][Full Text] [Related]
27. Thiol redox modulation of doxorubicin mediated cytotoxicity in cultured AIDS-related Kaposi's sarcoma cells.
Mallery SR; Clark YM; Ness GM; Minshawi OM; Pei P; Hohl CM
J Cell Biochem; 1999 May; 73(2):259-77. PubMed ID: 10227389
[TBL] [Abstract][Full Text] [Related]
28. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.
Kashani B; Zandi Z; Karimzadeh MR; Bashash D; Nasrollahzadeh A; Ghaffari SH
Immunol Res; 2019 Dec; 67(6):505-516. PubMed ID: 32026322
[TBL] [Abstract][Full Text] [Related]
29. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
30. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
Dayekh K; Johnson-Obaseki S; Corsten M; Villeneuve PJ; Sekhon HS; Weberpals JI; Dimitroulakos J
Mol Cancer Ther; 2014 Nov; 13(11):2559-71. PubMed ID: 25189541
[TBL] [Abstract][Full Text] [Related]
31. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
Bonavida B; Tsuchitani T; Zighelboim J; Berek JS
Gynecol Oncol; 1990 Sep; 38(3):333-9. PubMed ID: 2227544
[TBL] [Abstract][Full Text] [Related]
32. Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
Smith TA; Phyu SM; Akabuogu EU
Anticancer Res; 2016 Jan; 36(1):87-93. PubMed ID: 26722031
[TBL] [Abstract][Full Text] [Related]
33. Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen.
Bhatia S; Blick T; Pinto C; Waltham M; Monkman J; Ivanova E; Pollock PM; Nagaraj SH; Wiegmans AP; Haviv I; Simpson KJ; Thompson EW
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365878
[TBL] [Abstract][Full Text] [Related]
34. Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis.
Mashima T; Udagawa S; Tsuruo T
J Cell Physiol; 2001 Sep; 188(3):352-8. PubMed ID: 11473362
[TBL] [Abstract][Full Text] [Related]
35. In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer.
McCarthy M; Auda G; Agrawal S; Taylor A; Backstrom Z; Mondal D; Moroz K; Dash S
Exp Mol Pathol; 2014 Aug; 97(1):6-15. PubMed ID: 24780744
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.
Gariboldi MB; Ravizza R; Molteni R; Osella D; Gabano E; Monti E
Cancer Lett; 2007 Dec; 258(2):181-8. PubMed ID: 17920763
[TBL] [Abstract][Full Text] [Related]
37. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status.
Wang YA; Johnson SK; Brown BL; McCarragher LM; Al-Sakkaf K; Royds JA; Dobson PR
Int J Cancer; 2008 Oct; 123(7):1536-44. PubMed ID: 18634052
[TBL] [Abstract][Full Text] [Related]
38. Modulation of DNA damage response and induction of apoptosis mediates synergism between doxorubicin and a new imidazopyridine derivative in breast and lung cancer cells.
El-Awady RA; Semreen MH; Saber-Ayad MM; Cyprian F; Menon V; Al-Tel TH
DNA Repair (Amst); 2016 Jan; 37():1-11. PubMed ID: 26590797
[TBL] [Abstract][Full Text] [Related]
39. Growth factors and chemotherapeutic modulation of breast cancer cells.
Ciftci K; Su J; Trovitch PB
J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904
[TBL] [Abstract][Full Text] [Related]
40. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
